Insulin degludec: pharmacokinetics in patients with renal impairment.
about
Interactions between kidney disease and diabetes: dangerous liaisonsThe treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesConcentrated insulins: the new basal insulinsManagement of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic controlSafety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesPatient safety and minimizing risk with insulin administration - role of insulin degludecOverview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.A review of the pharmacological properties of insulin degludec and their clinical relevance.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patientsInsulin degludec: pharmacokinetic properties in subjects with hepatic impairmentInsulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Special considerations for the treatment of chronic kidney disease in the elderly.Clinical use of the co-formulation of insulin degludec and insulin aspart.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Degludec: the new ultra-long insulin analogue.Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.Insulin degludec overdose may lead to long-lasting hypoglycaemia through its markedly prolonged half-life.
P2860
Q26740630-D3565DB5-1001-4837-94F5-E3D37708BCC7Q26744317-1A2A4CA0-5DC8-4EDE-BE01-2F149EE09072Q26750438-17B00433-C9AC-4F7F-BE6F-F872DFF91973Q26766259-E3D95FBA-32BE-44CF-94AB-CBFE52B99DFAQ26778763-CE2BA340-D9FF-460C-B11A-46E2F4594606Q26784381-A2FEE4A8-4964-447D-91EC-F87682C6315AQ27025548-0A1979D3-7683-4C31-9677-2B80B0162BBCQ31025919-7157A1C2-C30D-479E-8052-BA55D3F71121Q34436383-710CABAA-7480-4DDC-9732-FB8B66363597Q36637960-45BA719C-2B43-421B-B1CB-0744276FB1D5Q37506417-D4A4930A-9092-4CB0-9A8E-062643B0A5A7Q38241834-B85A4ADB-4B68-4D15-B38E-8FA362CC155FQ38737061-A4F6EC7C-BD4F-4CC9-AC1E-83EA4CAFC913Q38887939-C5FCDA47-A02C-468F-BFC0-646273F9EF18Q38970550-77A54008-9926-4A7E-B132-8CF5968B5291Q39160771-C45CA6D1-D4F3-4285-9246-F39129574338Q41564970-D8A4C6C6-2568-4F1C-A1F8-99720E02EB65Q42398691-49F6E5BF-0B00-488D-AFD4-2E0AFE2B2B3BQ48232532-7C933011-41BF-4DFE-9F49-6C71A3B9A224
P2860
Insulin degludec: pharmacokinetics in patients with renal impairment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insulin degludec: pharmacokinetics in patients with renal impairment.
@en
Insulin degludec: pharmacokinetics in patients with renal impairment.
@nl
type
label
Insulin degludec: pharmacokinetics in patients with renal impairment.
@en
Insulin degludec: pharmacokinetics in patients with renal impairment.
@nl
prefLabel
Insulin degludec: pharmacokinetics in patients with renal impairment.
@en
Insulin degludec: pharmacokinetics in patients with renal impairment.
@nl
P2093
P2860
P1476
Insulin degludec: pharmacokinetics in patients with renal impairment.
@en
P2093
Carsten Roepstorff
Gerhard Arold
Hanne Haahr
István Kiss
Susanne Gammelgaard Bøttcher
Søren Klim
P2860
P2888
P304
P356
10.1007/S40262-013-0113-2
P577
2014-02-01T00:00:00Z